Seeing the brain differently
makes a world of difference

Learn More About Our Approach

News The latest from Sage

Press Releases

Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Events

Sage Therapeutics MOUNTAIN Topline Data Results

In the news

Learn more about the Sage Therapeutics Brand

See All News

Patients & Caregivers Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by CNS disorders.

Postpartum Depression

Major Depressive Disorder

Patient Advocacy Programs

See Our Resources for Patients

Healthcare Providers It’s an exciting time in neuroscience

At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to transform the practice of medicine and rethink how CNS disorders are treated.

Learn More About Our Approach

Clinical Trials A distinct approach to neuroscience drug development

Sage is committed to developing new medicines to treat life-altering CNS disorders.

Learn More About Our Ongoing Clinical Trials

Pipeline Advancing a Leading Brain Health Portfolio

We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential CNS therapeutics.

Compound
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Marketed

Depression Franchise

Preclinical
Phase 1
Phase 2
Phase 3
Marketed
SAGE-217*
Postpartum Depression (ROBIN)
Major Depressive Disorder (MDD) (MOUNTAIN, REDWOOD, SHORELINE)
Comorbid MDD & Insomnia (RAINFOREST)
Treatment Resistant Depression^

Neurology Franchise

Preclinical
Phase 1
Phase 2
Phase 3
Marketed
SAGE-324*
Essential Tremor
Epileptiform Disorders^
Parkinson's Disease^

Neuropsych Franchise

Preclinical
Phase 1
Phase 2
Phase 3
Marketed
SAGE-718**
Huntington's Disease
Executive Function

Early Development

Preclinical
Phase 1
Phase 2
Phase 3
Marketed
SAGE-904**
NMDA Hypofunction
SAGE-689*
GABA Hypofunction
Undisclosed
NMDA Hypofunction
Undisclosed
GABA Hypofunction
Key:
*GABA
**NMDA
^Planned Initiation
Learn More About Our Programs and Research

Careers Rethinking CNS to make life better for patients and their families

Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.

Experience Our Culture